bwthanks for your view re addressable market size, I had...

bw

thanks for your view re addressable market size, I had previously been advised by an offshore analyst whom I respect much that Omapro could generate peak sales of circa US$150-US$175m pa and I was surprised to see incidences of only 250-300 pa listed in their ODAC document and hence couldn't reconcile the est sales figures.

I would be very interested for anyone to cite a single example of any biotech anywhere in the world in the oncology space that goes direct into the US and generates an EBIT margin of 50% after allowing for sales/marketing/R&D and corporate overhead costs.

I think that you might be a little aggressive in applying an EBIT multiple of say 25x...PE yes, EBIT no. You need to tax effect

Rgds

Prof

PS...never heard of Avantogen, are they public?